Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
- N. Clarke, P. Wiechno, +13 authors F. Saad
- Medicine
- The Lancet. Oncology
- 1 July 2018
BACKGROUND
Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase… Expand
The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
- H. V. van Deventer, J. Burgents, +6 authors J. Ting
- Biology, Medicine
- Cancer research
- 15 December 2010
The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that… Expand
Migratory properties of pulmonary dendritic cells are determined by their developmental lineage
- H. Nakano, J. Burgents, +4 authors D. Cook
- Biology, Medicine
- Mucosal Immunology
- 1 July 2013
The chemokine receptor, CCR7, directs the migration of dendritic cells (DCs) from peripheral tissue to draining lymph nodes (LNs). However, it is unknown whether all pulmonary DCs possess migratory… Expand
Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.
- J. Coghill, M. J. Carlson, +4 authors J. Serody
- Biology, Medicine
- Blood
- 10 June 2010
CC-chemokine receptor 7 (CCR7) is expressed on the surface of naive T cells, and plays a critical role in their movement into secondary lymphoid tissue. Here, we show that murine T cells lacking CCR7… Expand
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
- T. P. Moran, J. Burgents, +5 authors J. Serody
- Biology, Medicine
- Vaccine
- 4 September 2007
While dendritic cell (DC) vaccines can protect hosts from tumor challenge, their ability to effectively inhibit the growth of established tumors remains indeterminate. Previously, we have shown that… Expand
The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice
- J. Burgents, T. P. Moran, M. West, N. Davis, R. Johnston, J. Serody
- Biology, Medicine
- Journal of immunotherapy
- 1 June 2010
We earlier showed that therapeutic vaccination of FVB/N mice with alphaviral replicon particles expressing rat neuET-VRP induced regression of established neu-expressing tumors. In this study, we… Expand
L‐Selectin Is Dispensable for T Regulatory Cell Function Postallogeneic Bone Marrow Transplantation
- M. J. Carlson, Leshara M Fulton, +7 authors J. Serody
- Medicine
- American journal of transplantation : official…
- 1 December 2010
In murine models, the adoptive transfer of CD4+/CD25+ regulatory T cells (Tregs) inhibited graft‐versus‐host disease (GvHD). Previous work has indicated a critical role for the adhesion molecule… Expand
Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene…
- A. Thiery‐Vuillemin, J. Bono, +15 authors M. Hussain
- Medicine
- 20 May 2020
5539Background: In the randomized Phase III PROfound trial (NCT02987543), olaparib significantly prolonged radiographic progression-free survival compared with physician’s choice of new hormonal ag...
Migratory properties of pulmonary dendritic cells are developmentally programmed
- D. Cook, J. Burgents, H. Nakano
- Biology
- 1 May 2012
- 3
Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.
- N. Clarke, A. Thiery‐Vuillemin, +13 authors F. Saad
- Medicine
- 26 February 2019
234Background: A Phase II trial showed that addition of olaparib (O) to abiraterone (A) led to significant radiographic progression-free survival benefit for patients (pts) with mCRPC vs placebo (P...